Augmentation of 3-methylcholanthrene-induced bioactivation in the human hepatoma cell line HepG2 by the calcium channel blocker nicardipine

Cancer Science

Volumn 101, Issue 3, 2010, Pages 652-657

  Hosaka, Takuomi ^a   Sekimoto, Masashi ^a   Nemoto, Kiyomitsu ^a   Degawa, Masakuni ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; MESSENGER RNA; NICARDIPINE;

ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CALCIUM CHANNEL BLOCKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; LIVER NEOPLASMS; METHYLCHOLANTHRENE; NICARDIPINE;

EID: 77949575643     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01454.x     Document Type: Article

References (42)

1. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004, 95:1-6.
2. Sugimura T, Wakabayashi K, Nakagama H, Nagao M. Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci 2004, 95:290-9.
3. Wood AW, Chang RL, Levin W. Metabolic activation of 3-methylcholanthrene and its metabolites to products mutagenic to bacterial and mammalian cells. Cancer Res 1978, 38:3398-404.
4. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes memorial lecture. Cancer Res 1982, 42:4875-917.
5. Shimizu Y, Nakatsuru Y, Ichinose M. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2000, 97:779-82.
6. Buters J, Quintanilla-Martinez L, Schober W. CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 2003, 24:327-34.
7. Degawa M, Kojima M, Hashimoto Y. Species difference between rats and mice in activities of enzymes activating aromatic amines: effect of dietary 3-methoxy-4-aminoazobenzene. Gann 1984, 75:966-75.
8. Degawa M, Kojima M, Hishinuma T, Hashimoto Y. Sex-dependent induction of hepatic enzymes for mutagenic activation of a tryptophan pyrolysate component, 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]-indole, by feeding in mice. Cancer Res 1985, 45:96-102.
9. Degawa M, Hishinuma T, Yoshida H, Hashimoto Y. Species, sex and organ differences in induction of a cytochrome P-450 isozyme responsible for carcinogen activation: effects of dietary hepatocarcinogenic tryptophan pyrolysate components in mice and rats. Carcinogenesis 1987, 8:1913-8.
10. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004, 279:23847-50.
11. Peters JM, Narotsky MG, Elizondo G, Fernandez-Salguero PM, Gonzalez FJ, Abbott BD. Amelioration of TCDD-induced teratogenesis in aryl hydrocarbon receptor (AhR)-null mice. Toxicol Sci 1999, 47:86-92.
12. Miyajima S, Nemoto K, Sekimoto M. Induction of hepatic cytochrome P450 isoforms by nicardipine at therapeutic doses in spontaneously hypertensive rats. J Toxicol Sci 2007, 32:79-90.
13. Konno Y, Nemoto K, Degawa M. Induction of hepatic cytochrome P450s responsible for the metabolism of xenobiotics by nicardipine and other calcium channel antagonists in the male rat. Xenobiotica 2003, 33:119-29.
14. Xu L, Li AP, Kaminski DL, Ruh MF. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. Chem Biol Interact 2000, 124:173-89.
15. Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol 1999, 18:95-105.
16. Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 2001, 134:271-81.
17. Fallone F, Villard PH, Decome L. PPARalpha activation potentiates AhR-induced CYP1A1 expression. Toxicology 2005, 216:122-8.
18. Jaruchotikamol A, Jarukamjorn K, Sirisangtrakul W, Sakuma T, Kawasaki Y, Nemoto N. Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes. Toxicol Appl Pharmacol 2007, 224:156-62.
19. Sekimoto M, Kawamagari H, Nakatani S, Nemoto K, Degawa M. Establishment of a human hepatoma cell line HepG2-A10 for a reporter gene assay of arylhydrocarbon receptor activators. Genes Environ 2007, 29:11-6.
20. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996, 24:899-905.
21. Hu SW, Chen CC, Kuo CY, Lin WH, Lin P. Increased cytochrome P4501B1 gene expression in peripheral leukocytes of municipal waste incinerator workers. Toxicol Lett 2006, 160:112-20.
22. Tian W, Osawa M, Horiuchi H, Tomita Y. Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci 2004, 95:491-5.
23. Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 1994, 48:923-36.
24. Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS, Sutter TR. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis 1997, 12:83-9.
25. Zhang ZY, Pelletier RD, Wong YN, Sugawara M, Zhao N, Littlefield BA. Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res Commun 2006, 341:399-407.
26. Kress S, Greenlee WF. Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 1997, 57:1264-9.
27. Zhang Y, Gupta A, Wang H. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 2005, 22:2023-34.
28. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000, 17:1189-97.
29. Yeh GC, Lopaczynska J, Poore CM, Phang JM. A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells. Cancer Res 1992, 52:6692-5.
30. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005, 26:1754-63.
31. Daujat M, Peryt B, Lesca P, Fourtanier G, Domergue J, Maurel P. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem Biophys Res Commun 1992, 188:820-5.
32. Kim HG, Han EH, Jeong HG. Effect of troglitazone on CYP1A1 induction. Toxicology 2008, 246:166-71.
33. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009, 385:269-72.
34. Li W, Harper PA, Tang BK, Okey AB. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol 1998, 56:599-612.
35. Köhle C, Bock KW. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 2007, 73:1853-62.
36. Flesher JW, Horn J, Lehner AF. Carcinogenicity of 1-hydroxy-3-methylcholanthrene and its electrophilic sulfate ester 1-sulfooxy-3-methylcholanthrene in Sprague-Dawley rats. Biochem Biophys Res Commun 1998, 243:30-5.
37. Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol 2007, 22:319-25.
38. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997, 80:1438-47.
39. Pahor M, Guralnik JM, Ferrucci L. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996, 348:493-7.
40. Sørensen HT, Olsen JH, Mellemkjaer L. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 2000, 89:165-70.
41. Rosenberg L, Rao RS, Palmer JR. Calcium channel blockers and the risk of cancer. JAMA 1998, 279:1000-4.
42. Olsen JH, Sørensen HT, Friis S. Cancer risk in users of calcium channel blockers. Hypertension 1997, 29:1091-4.